LAG3 immune inhibitors: a novel strategy for melanoma treatment
Melanoma, a highly aggressive skin cancer, poses significant challenges in treatment, particularly for advanced or metastatic cases. While immunotherapy, especially immune checkpoint inhibitors (ICIs) targeting CTLA-4 and PD-1, has transformed melanoma management, many patients experience limited re...
Saved in:
| Main Authors: | Renzheng Wu, Mingtang Zeng, Yuchen Zhang, Jianping He |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1514578/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies
by: Tuba N. Gide, et al.
Published: (2023-12-01) -
Early changes of peripheral circulating immune subsets induced by PD-1 inhibitors in patients with advanced malignant melanoma and non-small cell lung cancer
by: Simona Borilova, et al.
Published: (2024-12-01) -
Advances in immunotherapy for mucosal melanoma: harnessing immune checkpoint inhibitors for improved treatment outcomes
by: Zexing Shan, et al.
Published: (2024-07-01) -
Hyperdifferentiated murine melanoma cells promote adaptive anti-tumor immunity but activate the immune checkpoint system
by: Yukie Ando, et al.
Published: (2025-12-01) -
Association between history of viral infections and melanoma mortality
by: Nathan Shen, et al.
Published: (2024-11-01)